T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BFX
2651
DELISTED
BowFlex Inc.
BFX
| $135K | ﹤0.01% |
82,600
+53,700
| +186% | +$108K |
|
|
ASXC
2652
DELISTED
Asensus Surgical, Inc.
ASXC
| $134K | ﹤0.01% |
296,100
+86,400
| +41% | +$45K |
|
|
PRVB
2653
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $134K | ﹤0.01% |
29,559
+9,411
| +47% | +$42.9K |
|
|
CTAQ
2654
DELISTED
Carney Technology Acquisition Corp. II Class A Common Stock
CTAQ
| $130K | ﹤0.01% |
13,038
| – | – |
|
2655
Ocular Therapeutix
OCUL
$2.22B
| $129K | ﹤0.01% |
30,889
+4,981
| +19% | +$25.1K |
|
2656
Rigel Pharmaceuticals
RIGL
$762M
| $129K | ﹤0.01% |
10,871
-5,959
| -35% | -$80.6K |
|
2657
Workhorse Group
WKHS
$33.1M
| $129K | ﹤0.01% |
15
+3
| +25% | +$29.2K |
|
2658
DocGo
DCGO
$64.5M
| $128K | ﹤0.01% |
+12,805
| New | +$116K |
|
2659
GrowGeneration
GRWG
$108M
| $128K | ﹤0.01% |
36,503
+16,981
| +87% | +$78.4K |
|
2660
Westwater Resources
WWR
$75.2M
| $127K | ﹤0.01% |
111,000
| – | – |
|
2661
Dare Bioscience
DARE
$20.5M
| $126K | ﹤0.01% |
10,492
+5,609
| +115% | +$77K |
|
2662
ARKO Corp
ARKO
$505M
| $125K | ﹤0.01% |
+13,231
| New | +$126K |
|
2663
Rush Street Interactive
RSI
$2.85B
| $125K | ﹤0.01% |
33,780
+3,902
| +13% | +$20.6K |
|
|
AMPS
2664
DELISTED
Altus Power
AMPS
| $125K | ﹤0.01% |
11,313
-15,986
| -59% | -$152K |
|
|
ASTR
2665
DELISTED
Astra Space, Inc. Class A Common Stock
ASTR
| $125K | ﹤0.01% |
13,498
-20,311
| -60% | -$343K |
|
|
BRY
2666
DELISTED
Berry Corp
BRY
| $124K | ﹤0.01% |
16,409
+2,760
| +20% | +$23.3K |
|
2667
Ring Energy
REI
$349M
| $124K | ﹤0.01% |
53,228
+25,879
| +95% | +$70.6K |
|
|
XXII
2668
22nd Century Group
XXII
$1.42M
| – | – |
0
| – | – |
|
|
TWKS
2669
DELISTED
Thoughtworks Holding, Inc. Common Stock
TWKS
| $124K | ﹤0.01% |
11,797
-2,213,199
| -99% | -$31.2M |
|
2670
Noodles & Co
NDLS
$100M
| $123K | ﹤0.01% |
3,260
-514
| -14% | -$20.4K |
|
2671
Vipshop
VIPS
$6.8B
| $123K | ﹤0.01% |
14,600
-2,500
| -15% | -$24.9K |
|
|
LICY
2672
DELISTED
Li-Cycle Holdings Corp.
LICY
| $123K | ﹤0.01% |
2,870
+1,293
| +82% | +$70.3K |
|
|
SFR
2673
DELISTED
Appreciate Holdings, Inc. Class A Common Stock
SFR
| $123K | ﹤0.01% |
12,361
| – | – |
|
2674
Fossil Group
FOSL
$330M
| $122K | ﹤0.01% |
35,617
+3,426
| +11% | +$17.6K |
|
2675
indie Semiconductor
INDI
$875M
| $122K | ﹤0.01% |
+16,548
| New | +$122K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.